Skip to main content

FDA Clears Bio-Rad Blood Typing, Screening System

NEW YORK (360Dx) – Bio-Rad Laboratories said after the close of the market on Monday that the US Food and Drug Administration has cleared the company's IH-500 automated random access system for blood typing and screening.

Designed for small and medium-sized labs, the system offers automated blood typing and screening based on gel card technology with minimum user intervention. It can process Bio-Rad's entire range of IH gel cards for ABO blood grouping, reverse testing, phenotype, Rh-subgroups, antibody screening, antibody identification, single antigen testing, direct AHG testing, and crossmatch, the company said.

Bio-Rad said last week that the FDA cleared its Lyme disease assay.